Generic Drugs Direct Purchaser Settlement Antitrust Litigation

Did your company purchase generic pharmaceutical drugs directly from a pharmaceutical manufacturer between May 1, 2009 through December 31, 2019?

If so, you may be entitled to compensation as a result of $350,000,000 in settlements.

Settlement Total
Settlement Total
Eligible Purchase Dates
5/1/09 - through 12/31/19
Eligible Purchase Dates



Background Information

Plaintiffs allege that Sun Pharmaceutical Industries, Inc., Caraco Pharmaceutical Laboratories, Ltd., Mutual Pharmaceutical Company, Inc., URL Pharma, Inc., and Taro Pharmaceuticals U.S.A., Inc. conspired with other generic drug manufacturers to fix, maintain, and stabilize prices, rig bids, and engage in market manipulations with respect to certain generic drugs, causing direct purchasers to pay inflated prices. The aforementioned Defendants deny these claims but have agreed to settle the lawsuit for $85,000,000 collectively. In addition, there has been another settlement reached with Sandoz Inc. and Fougera Pharmaceuticals Inc.(subsidiaries of Sandoz Group AG) for $265,000,000. There are still claims being litigated against additional non-settling Defendants, which may result in additional settlements.

Settlement Information

Filing Deadline: May 6, 2024

Settlement Class- Who Qualifies+

A Settlement Class has been certified that includes all persons or entities, and their successors and assigns, that directly purchased one or more of the Named Generic Drugs from one or more Defendants (see Case Documents tab) in the United States and its territories and possessions, at any time during the period from May 1, 2009 through December 31, 2019. 

Excluded from the Settlement Class are Defendants and their present and former officers, directors, management, employees, subsidiaries, or affiliates, judicial officers and their personnel, and all governmental entities. The Named Generic Drugs and Defendants are available in the Case Documents tab of this website.

Case Name+

In re: Generic Pharmaceuticals Pricing Antitrust Litigation, Case No. 2:16-MD-02724.

Settlement Details+

Three groups of Defendants have settled for a total of $350,000,000 (Settlement Fund) as broken down below:

  •  Sun Pharmaceutical Industries, Inc. and its affiliates Caraco Pharmaceutical Laboratories, Ltd., Mutual Pharmaceutical Company, Inc., and URL Pharma, Inc. have agreed to pay $17,357,000
  • Taro Pharmaceuticals U.S.A., Inc have agreed to pay $67,643,000. 
  • Sandoz Inc. and Fougera Pharmaceuticals Inc.(subsidiaries of Sandoz Group AG) have agreed to pay $265,000,000

These amounts will be be reduced by costs of attorneys fees and expenses, settlement administration costs, service awards for the class representatives and other amounts. If certain circumstances occur, it is possible the Settlement Fund may be increased.


Class members are not required to sign up with any third-party service in order to participate in the monetary relief, but may instead file their claim directly with the Claims Administrator. No-cost assistance will be available from the Class Administrator and Class Counsel during the claims-filing period. For additional information class members may visit court approved website for this case,

Please note this website and its contents are not substitutes for legal advice. Nothing in this website should be construed as legal advice. Class Action Settlement House, LLC works with companies and organizations to assist them in the filing of claims in various class action settlements. However, Class Action Settlement House, LLC is not a law firm and cannot provide legal representation or legal advice. If you are seeking legal advice, please contact counsel of your choice to obtain legal advice.


Receive More Information

Receive more information on this case by completing the form below.